Fig. 4.
Fig. 4. p210-transduced cells express. / BCR/ABL, and imatinib mesylate inhibits p210BCR/ABL phosphorylation. Parental (untransduced), eGFP+, and p210-eGFP-transduced (p210+) NK92 cells (5 × 104 cells) were incubated with or without imatinib mesylate for 48 hours in the presence or absence of IL-2 and analyzed by Western blot with antiphosphotyrosine (α-pY) or anti-Abl antibody. Cells treated with imatinib mesylate demonstrate a dose-dependent inhibition of p210BCR/ABL phosphorylation, both in the presence and absence of IL-2. p210BCR/ABLexpression is present in all p210-transduced NK92 and K562 (positive control) cells.

p210-transduced cells express

BCR/ABL, and imatinib mesylate inhibits p210BCR/ABL phosphorylation. Parental (untransduced), eGFP+, and p210-eGFP-transduced (p210+) NK92 cells (5 × 104 cells) were incubated with or without imatinib mesylate for 48 hours in the presence or absence of IL-2 and analyzed by Western blot with antiphosphotyrosine (α-pY) or anti-Abl antibody. Cells treated with imatinib mesylate demonstrate a dose-dependent inhibition of p210BCR/ABL phosphorylation, both in the presence and absence of IL-2. p210BCR/ABLexpression is present in all p210-transduced NK92 and K562 (positive control) cells.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal